Phase I dose escalation of single-agent vinblastine in dogs

Journal of Veterinary Internal Medicine

Volumn 22, Issue 6, 2008, Pages 1397-1402

  Bailey, Dennis B ^a   Rassnick, K M ^a   Kristal, O ^b,c,d   Chretin, J D ^c,e   Balkman, C E ^a  

^a Department of Obstetrics Gynecology   (United States)

^b Animal Cancer Specialists   (United States)

^c TUFTS UNIVERSITY   (United States)

^d Chavat Daat Veterinary Specialty Center   (Israel)

^e Los Angeles Neuropsychology Group   (United States)

Author keywords

Canine; Chemotherapy; Oncology; Oncology treatment

Indexed keywords

ANTINEOPLASTIC AGENT; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LYMPHOMA; MALE; VINBLASTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 57149096686     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0196.x     Document Type: Article

References (41)

1. Rosenthal RC. Clinical applications of vinca alkaloids. J Am Vet Med Assoc 1981;179:1084, 1086.
2. Golden DL, Langston VC. Uses of vincristine and vinblastine in dogs and cats. J Am Vet Med Assoc 1988;193:1114-1117.
3. Rowinsky EK. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, Practice and Principles, 4th ed. Philadelphia, PA: Lipincott Williams and Wilkins; 2006:237-282.
4. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor - 41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
5. Davies DR, Wyatt KM, Jardine JE, et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124-130.
6. Trumel C, Bourges-Abella N, Touron C, et al. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: A retrospective study in fourteen dogs with mast cell tumours. J Vet Med A Physiol Pathol Clin Med 2005;52:275-279.
7. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
8. Hayes A, Adams V, Smith K, et al. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet Comp Oncol 2007;5:168-176.
9. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp Oncol 2007;5:156-167.
10. Boggs DR, Athens JW, Haab OP, et al. Leukokinetic studies. VII. Morphology of the bone marrow and blood of dogs given vinblastine sulfate. Blood 1964;23:53-67.
11. Creasey WA, Scott AI, Wei CC, et al. Pharmacological studies with vinblastine in the dog. Cancer Res 1975;35:1116-1120.
12. Crow SE. Treatment of a mast cell tumor in a dog. Mod Vet Pract 1977;58:766-767.
13. Madewell BR, Theilen GH. Chemotherapy. In: Theilen GH, Madewell BR, eds. Veterinary Cancer Medicine. Philadelphia, PA: Lea and Febiger; 1979:95-112.
14. Chu E, DeVita VT. Principles of medical oncology. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:295-306.
15. Veterinary Co-Operative Oncology Group. Veterinary co-operative oncology group - Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
16. Brooks DG. Acute tumor lysis syndrome. Compend Cont Educ Pract Vet 1995;17:1103-1106.
17. Poirier VJ, Burgess KE, Adams WM, Vail DM. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 2004;18:536-539.
18. Rassnick KM, Moore AS, Northrup NC, et al. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas. Am J Vet Res 2006;67:510-516.
19. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-5438.
20. Arrington KA, Legendre AM, Tabeling GS, Frazier DL. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994;55:1587-1592.
21. Ogilvie GK, Moore AS, Curtis CR. Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987). J Am Vet Med Assoc 1989;195:1399-1403.
22. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
23. Page RL, Macy DW, Thrall DE, et al. Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. Cancer Res 1988;48:288-290.
24. McCaw DL, Miller MA, Bergman PJ, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997;11:375-378.
25. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
26. Timmer-Bonte JNH, Adang EMM, Termeer E, et al. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290-296.
27. Chretin JD, Rassnick KM, Shaw NA, et al. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma; a double-blind, placebo-controlled study. J Vet Intern Med 2007;21:141-148.
28. Flory AB, Rassnick KM, Al-Sarraf R, et al. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med 2008;22:164-171.
29. Marangolo M, Bengala C, Conte PF, et al. Dose and outcome: The hurdle of neutropenia (review). Oncol Rep 2006;16:233-248.
30. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988;121-141.
31. Mutsaers AJ, Glickman NW, DeNicola DB, et al. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 2002;220:1813-1817.
32. Ogilvie GK, Vail DM, Klein MK, et al. Weekly administration of low-dose doxorubicin for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1991;198:1762-1764.
33. Jackson DV, Spurr CL Jr., Caponera ME, et al. Vinblastine infusion in non-Hodgkin's lymphomas: Lack of total cross-resistance with vincristine. Cancer Investig 1987;5:535-539.
34. Stolinsky DC, Hum GJ, Jacobs EM, et al. Clinical trial of weekly doses of vinblastine (NSC-49842) combined with vincristine (NCS-67574) in malignant lymphomas and other neoplasms. Cancer Chemother Rep 1973;57:477-480.
35. Ferguson PJ, Phillips JR, Selner M, Cass CE. Differential activity of vincristine and vinblastine against cultured cells. Cancer Res 1984;44:3307-3312.
36. Ferguson PJ, Cass CE. Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: The basis of differential toxicity. Cancer Res 1985;45:5480-5488.
37. Rivera-Fillat MP, Pallares-Trujillo J, Domenech C, Grau-Oliete MR. Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br J Pharmacol 1988;93:902-908.
38. Frei E, Elias A III, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027-2037.
39. Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-1974.
40. Rassnick KM, Mauldin GE, al Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989-2000). J Vet Intern Med 2002;16:576-580.
41. LeBlanc AK, Mauldin GE, Milner RJ, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Comp Oncol 2006;4:21-32.